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FLUDARABINE BASED CONDITIONING REGIMEN FOR ALLOGENEIC
STEM CELL TRANSPLANTATION FOR MULTIPLY TRANSFUSED PA-
TIENTS WITH FANCONI’S ANEMIA
George, B., Mathews, V., Srivastava, A., Chandy, M. Department of
Haematology, Christian Medical College, Vellore, Tamil Nadu, India.
Multiply transfused patients with severe aplastic anemia or Fan-
coni’s anemia (FA) have an increased risk of graft rejection after
allogeneic stem cell transplantation (SCT) which can be as high as
30%. Intense immunosuppression in the conditioning regimen is
therefore required which is achieved by high doses of cyclophos-
phamide and addition of antithymocyte globulin (ATG). Since
such dosages of cyclophosphamide cannot be administered to pa-
tients with FA, we have evaluated ﬂudarabine based conditioning
regimen for SCT in these patients.
Three children with FA underwent allogeneic SCT using ﬂu-
darabine based conditioning regimen. All donors were HLA
matched sibling or parents. Conditioning regimen consisted of
ﬂudarabine (30 mg/m2/day for 6 days), cyclophosphamide (10mg/
kg/day for 2 days) and ATG (ATGAM 10 mg/kg/day for 4 days).
All were males with a mean age of 12 years (range: 8-15). The
median time from diagnosis to BMT was 32 months (range:18-54)
with the average number of red cell transfusions being 25 (range:
15-40). Two patients received G-CSF stimulated bone marrow
while one received G-CSF stimulated PBSC. The regimen was
well tolerated with no major toxicities. All patients engrafted with
the average time to ANC  500/mm3 being 15 days (range: 13-17)
and time to unsupported platelet count 20,000/mm3 being 17
days (range: 15-18). None of the patients developed acute graft
versus host disease. One patient developed secondary graft rejec-
tion on day 59 and expired on day 72 due to fungal pneumonia.
Chimerism analysis using VNTR on day 60 showed a pattern
consistent with rejection. Other 2 patients are well and in complete
remission(CR) with a median follow up of 12 and 26 months.
Optimal conditioning regimens for patients with multiply trans-
fused FA remains to be deﬁned. Addition of ﬂudarabine to the
conditioning regimen for SCT in FA can provide additional im-
munosuppression for engraftment without increasing toxicity.
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PATIENTS WITH SEVERE APLASTIC ANEMIA CAN BE ALLOGRAFTED
SUCCESFULLY WITHOUT ANTI-THYMOCYTE GLOBULIN, USING A NON-
MYELOABLATIVE CONDITIONING REGIMEN
Go´mez-Almaguer, D.1, Vela-Ojeda, J.2, Jaime-Pe´rez, J.C.1, Gutie´r-
rez-Aguirre, C.H.1, Cantu´-Rodrı´guez, O.G.1, Go´mez-Rangel, D.3,
Ruiz-Argu¨elles, G.J.3 1. Hospital Universitario UANL, Monterrey,
Nuevo Leo´n, Mexico; 2. Centro Me´dico La Raza IMSS, Me´xico, DF,
Mexico; 3. Centro de Hematologı´a y Medicina Interna, Puebla, Puebla,
Mexico.
Introduction: We investigated the effectivity of ﬂudarabine-
cyclophosphamide based conditioning regimen without ATG or
lymph node irradiation in 16 SAA heavily transfused patients stud-
ied in three different medical centers in Me´xico. The patients have
had no response to previous pharmacologic conventional treat-
ment, including androgens and immunosuppressive therapy. Ma-
terial and Methods: The SAA patients were included in three
conditioning groups, 5 cases received oral busulphan 4mg/kg/day/
2days, CY 350mg/m2/day/3days and ﬂudarabine 30/mg/m2/day/3
days, in the second group (ﬁve cases) no busulphan was used and
CY, 45mg/kg/day/2 days was given. In the third group, ﬂudarabine
50mg/day/5days and CY 1.5g/m2/day/3 days were utilized. For
GVHD prophylaxis cyclosporine and methotrexate was used. For
infection prophylaxis the patients received ciproﬂoxacin, ﬂucon-
azole and acyclovir. All the patients received peripheral blood stem
cells from their HLA identical siblings. The donors were stimu-
lated with G-CSF 10/Kg/4 days. Results: the age range was 4 to
51 years. The peripheral blood stem cell product was infused in 1-3
days, with a median dose of 7.1 x106 CD34/kg. The patients were
followed for a median of 24 months (range,4 to 77). At a median of
day 12 an ANC 0.5x109/L was reached, and also the platelet
count reached 20,000x109/L at the same day. Acute grade I-II
GVHD occurred in 2 patients, whereas limited chronic GVHD
presented in 3 cases. Ten patients (62%) achieved sustained en-
graftment and are currently in clinical remission. Two patients
failed to engraft and 4 failed to achieved sustained engraftment; 2
of these individuals died as a result of the graft failure, 2 survive
with high transfusion requirements, whereas 2 received a second
transplant using the same donor and conditioning regimen, and
achieved sustained engraftment. Currently 14/16 patients are alive,
whereas 12/16 (75%) remain in a complete remission. Discussion:
These ﬂudarabine based conditioning regimens have acceptable
toxicity, low cost and allows durable engraftment, representing a
viable alternative to traditional more citotoxic conditioning for
SAA patients who receive a stem cell allograft.
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IMMUNOSUPPRESSION WITH ATG F ALLOWS FOR SUCCESSFUL TRANS-
PLANTATION FROM MISMATCHED UNRELATED DONORS
Zander, A.R., Zabelina, T., Ayuk, F., Kabisch, H., Erttmann, R., Fehse,
N., Fehse, B., Wolschke, C., Stute, N., Kratochwille, A., Panse, J.,
Eiermann, T.H., Kroger, N.M. Bone Marrow Transplantation Centre,
University of Hamburg, Hamburg, Germany.
Allogeneic bone marrow transplantation of matched unrelated
donors carries an increased risk of Graft-versus-Host-Disease and
transplant related mortality. We introduced ATG Fresenius [me-
dian dose 90mg/kg bw] as part of the conditioning for prevention
of serious GvHD. We compared 48 patients with mismatched
transplant with 170 patients with an HLA matched transplant. The
mismatch involved of 1 or 2 loci. The groups differed in age. HLA
match 33y (0,9-61), HLA mismatch 21y (0,9-51), and graft source
BM vs. PBSC 67/33% in match vs. 83/17% in mismatch.
They were comparable in diagnoses, stage of disease and condi-
tioning. Conclusion: Addition of ATG Fresenius permits hemo-
poietic stem cell transplantation from mismatched donors with
results comparable [regarding GvH control, TRM and survival] to
HLA matched donors.
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A HIGH THROUGHPUT SNP BASED KIR GENOTYPING SYSTEM FOR USE
IN ALLOGENEIC TRANSPLANTATION AND OUTCOMES ANALYSES
Houtchens, K.A., Nichols, R.J., Boal, H.E., Herman, T.M., Trachten-
berg, E.A. Children’s Hospital Oakland Research Institute, Oakland,
CA.
Recent evidence suggests that interactions between an individu-
al’s Killer Immunoglobulin-like Receptor (KIR) molecular proﬁle
and Human Leukocyte Antigen (HLA) ligands may play an im-
portant role in stem cell transplant outcome (Ruggerri et al., Science
2002; Gagne et al., Human Immunology 2002). If these early results
are replicated, it may be necessary to assess KIR genotypes as part
of the donor selection process. Like the HLA genes, the KIR genes
are highly polymorphic. As the characterization of the total diver-
sity of these genes is still in its infancy, novel variants are reported
frequently. We are developing a novel, high-throughput single
nucleotide polymorphism (SNP)-based KIR genotyping method-
ology. In this assay, the nucleic acid mass differences generated in
a SNP-based primer extension reaction are analyzed on a matrix-
assisted laser desorption/ionization time-of-ﬂight mass spectrom-
eter (MALDI-TOF). The method uses 384-well microarray chips,
and is by nature both highly accurate and rapid. More importantly
Table.
Results HLA Match HLA Mismatch P
GvHD 2–4 43% 33% 0,2
GvHD 3–4 22% 10% 0,06
Chronic GvHD 38% 38% 0,9
5 year DFS 45% 51% 0,5
Overall survival 50% 51% 0,7
TRM 33% 25% 0,2
Relapse rate 5 years 31% 30% 0,6
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